医学
烧蚀
临床终点
心房颤动
导管消融
随机对照试验
心脏病学
外科
试验装置豁免
导管
内科学
临床试验
作者
Elad Anter,Moussa Mansour,Devi G. Nair,Dinesh C Sharma,Tyler L. Taigen,Petr Neužil,Erich L. Kiehl,Josef Kautzner,Jose Osorio,Stavros Mountantonakis,Andrea Natale,John D. Hummel,Anish K. Amin,Usman R. Siddiqui,Doron Harlev,Paul Hultz,Shufeng Liu,Birce Önal,Khaldoun G. Tarakji,Vivek Y. Reddy
出处
期刊:Nature Medicine
[Nature Portfolio]
日期:2024-05-17
卷期号:30 (8): 2303-2310
被引量:42
标识
DOI:10.1038/s41591-024-03022-6
摘要
Clinical outcomes of catheter ablation for atrial fibrillation (AF) are suboptimal due, in part, to challenges in achieving durable lesions. Although focal point-by-point ablation allows for the creation of any required lesion set, this strategy necessitates the generation of contiguous lesions without gaps. A large-tip catheter, capable of creating wide-footprint ablation lesions, may increase ablation effectiveness and efficiency. In a randomized, single-blind, non-inferiority trial, 420 patients with persistent AF underwent ablation using a large-tip catheter with dual pulsed field and radiofrequency energies versus ablation using a conventional radiofrequency ablation system. The primary composite effectiveness endpoint was evaluated through 1 year and included freedom from acute procedural failure and repeat ablation at any time, plus arrhythmia recurrence, drug initiation or escalation or cardioversion after a 3-month blanking period. The primary safety endpoint was freedom from a composite of serious procedure-related or device-related adverse events. The primary effectiveness endpoint was observed for 73.8% and 65.8% of patients in the investigational and control arms, respectively (P < 0.0001 for non-inferiority). Major procedural or device-related complications occurred in three patients in the investigational arm and in two patients in the control arm (P < 0.0001 for non-inferiority). In a secondary analysis, procedural times were shorter in the investigational arm as compared to the control arm (P < 0.0001). These results demonstrate non-inferior safety and effectiveness of the dual-energy catheter for the treatment of persistent AF. Future large-scale studies are needed to gather real-world evidence on the impact of the focal dual-energy lattice catheter on the broader population of patients with AF. ClinicalTrials.gov identifier: NCT05120193 .
科研通智能强力驱动
Strongly Powered by AbleSci AI